What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized? [11]

Clinical Infectious Diseases

Volumn 42, Issue 12, 2006, Pages 1813-1814

  Tattevin, Pierre ^a   Camus, Christophe ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

BACTERICIDAL ACTIVITY; BODY WEIGHT; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOXICITY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; PNEUMONIA; POSTANTIBIOTIC EFFECT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR;

ACETAMIDES; ANTI-BACTERIAL AGENTS; FEVER; HUMANS; NEUTROPENIA; OXAZOLIDINONES; VANCOMYCIN;

EID: 33744779875     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504431     Document Type: Letter

References (10)

1. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42:597-607.
2. Murray BE, Nannini EC. Glycopeptides (vancomycin and teicoplanin), sireptogramins (quinupristin-dalfopristin), and lipopeptides (daptomycin). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Vol. 1. Philadelphia: Churchill Livingstone, 2005:417-34.
3. Le Normand Y, Milpied N, Kergueris MF, Harousseau JL. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput 1994; 36:121-5.
4. Kergueris MF, Le Normand Y, Jahan P Milpied N. Application of USC*PACK clinical programs to vancomycin in neutropenic patients. Int J Biomed Comput 1994; 36:163-5.
5. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42(Suppl 1):S40-50.
6. American Thoracic Society-Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
7. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42(Suppl 1):S35-9.
8. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18:533-43.
9. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
10. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis 2002; 35:347-8.